- PROFESSOR Oncological Sciences
- PROFESSOR Medicine, Hematology and Medical Oncology
M.D., University of Algiers
Residency, University Paris VII (Interne des hopitaux de Paris)
M.S. (DEA), University Paris VII
Ph.D., Stanford University and University Paris VII
Postdoctoral Fellow, Stanford University
Immunology-Department of Pathology
Miriam Merad, MD, PhD, is a Professor of Oncological Science and of Medicine (Hem/Onc division) at the Icahn School of Medicine at Mount Sinai in New York. Dr. Merad was trained as an Oncologist in France and obtained her PhD in immunology at Stanford University and University of Paris VII. She was recruited to Mount Sinai School of Medicine in 2004 and was promoted to the rank of Associate Professor with Tenure in 2007 and to Full Professor in 2010.
In 2010 Dr. Merad became the program leader of the Cancer immunology immunotherapy group at The Tisch Cancer Institute and the director of the Human Immunomonitoring center, which goal is to identify novel immune biomarkers of disease and response to therapy in patients with cancer and allergic disease Dr. Merad also serves as the Associate Director for the MD PhD program at Mount Sinai Medical School.
Dr. Merad’s laboratory studies the mechanisms that regulate the development and function of innate myeloid cells including dendritic cells and macrophages. One of the major goals of her laboratory is to identify the contribution of these cells to the development and progression of tumor cells. Dr. Merad’s hypothesis suggests that tumors do not consist of a homogenous mass of genetically altered cells but rather include a large amount of innate myeloid cells that significantly contribute to tumor development. Dr. Merad established that tumor infiltrating dendritic cells could be targeted in vivo to promote the induction of tumor specific immunity. Currently, she is examining the contribution of tumor infiltrating macrophages to tumor progression and response to conventional and targeted therapies.
In 2013, Dr. Merad was the primary organizer of the prestigious Keystone conference on dendritic cell biology and was elected to the “American Society of Clinical Investigation”. She has authored more than 100 primary papers and review articles in high profile journals and obtained extensive NIH funding for her studies on dendritic cells and macrophage biology in mice and humans.
Please visit Dr. Merad's Lab website: http://icahn.mssm.edu/research/labs/merad-laboratory
Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annual review of immunology 2013; 31.
Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, Becker CD, See P, Price J, Lucas D, Greter M, Mortha A, Boyer SW, Forsberg EC, Tanaka M, van Rooijen N, García-Sastre A, Stanley ER, Ginhoux F, Frenette PS, Merad M. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 2013 Apr; 38(4).
Yu CI, Becker C, Wang Y, Marches F, Helft J, Leboeuf M, Anguiano E, Pourpe S, Goller K, Pascual V, Banchereau J, Merad M, Palucka K. Human CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal effector T cells via the cytokine TGF-β. Immunity 2013 Apr; 38(4).
Idoyaga J, Fiorese C, Zbytnuik L, Lubkin A, Miller J, Malissen B, Mucida D, Merad M, Steinman RM. Specialized role of migratory dendritic cells in peripheral tolerance induction. The Journal of clinical investigation 2013 Feb; 123(2).
Greter M, Lelios I, Pelczar P, Hoeffel G, Price J, Leboeuf M, Kündig TM, Frei K, Ginhoux F, Merad M, Becher B. Stroma-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia. Immunity 2012 Dec; 37(6).
Chow A, Huggins M, Ahmed J, Hashimoto D, Lucas D, Kunisaki Y, Pinho S, Leboeuf M, Noizat C, van Rooijen N, Tanaka M, Zhao ZJ, Bergman A, Merad M, Frenette PS. CD169⁺ macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nature medicine 2013 Apr; 19(4).
Helft J, Manicassamy B, Guermonprez P, Hashimoto D, Silvin A, Agudo J, Brown BD, Schmolke M, Miller JC, Leboeuf M, Murphy KM, García-Sastre A, Merad M. Cross-presenting CD103+ dendritic cells are protected from influenza virus infection. The Journal of clinical investigation 2012 Nov; 122(11).
Scheiermann C, Kunisaki Y, Lucas D, Chow A, Jang JE, Zhang D, Hashimoto D, Merad M, Frenette PS. Adrenergic nerves govern circadian leukocyte recruitment to tissues. Immunity 2012 Aug; 37(2).
Greter M, Helft J, Chow A, Hashimoto D, Mortha A, Agudo-Cantero J, Bogunovic M, Gautier EL, Miller J, Leboeuf M, Lu G, Aloman C, Brown BD, Pollard JW, Xiong H, Randolph GJ, Chipuk JE, Frenette PS, Merad M. GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity 2012 Jun; 36(6).
Hoeffel G, Wang Y, Greter M, See P, Teo P, Malleret B, Leboeuf M, Low D, Oller G, Almeida F, Choy SH, Grisotto M, Renia L, Conway SJ, Stanley ER, Chan JK, Ng LG, Samokhvalov IM, Merad M, Ginhoux F. Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages. The Journal of experimental medicine 2012 Jun; 209(6).
Jiao J, Sastre D, Fiel MI, Lee UE, Ghiassi-Nejad Z, Ginhoux F, Vivier E, Friedman SL, Merad M, Aloman C. Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Hepatology (Baltimore, Md.) 2012 Jan; 55(1).
Hashimoto D, Chow A, Greter M, Saenger Y, Kwan WH, Leboeuf M, Ginhoux F, Ochando JC, Kunisaki Y, van Rooijen N, Liu C, Teshima T, Heeger PS, Stanley ER, Frenette PS, Merad M. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. The Journal of experimental medicine 2011 May; 208(5).
Chow A, Lucas D, Hidalgo A, Méndez-Ferrer S, Hashimoto D, Scheiermann C, Battista M, Leboeuf M, Prophete C, van Rooijen N, Tanaka M, Merad M, Frenette PS. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. The Journal of experimental medicine 2011 Feb; 208(2).
Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science (New York, N.Y.) 2010 Nov; 330(6005).
Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science (New York, N.Y.) 2010 Feb; 327(5966).
Sathaliyawala T, O'Gorman WE, Greter M, Bogunovic M, Konjufca V, Hou ZE, Nolan GP, Miller MJ, Merad M, Reizis B. Mammalian target of rapamycin controls dendritic cell development downstream of Flt3 ligand signaling. Immunity 2010 Oct; 33(4).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Merad did not report having any of the following types of financial relationships with industry during 2013 and/or 2014: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Hess CSM Building Floor Tisch Cancer Inst, 5th Fl Room 118
1470 Madison Avenue
New York, NY 10029